Key result
MDR-TB, pulmonary TB, and empyema were significant risk factors for treatment delay ≥30 days in patients with pleural tuberculosis.
Observational (n=723)
MDR-TB, pulmonary TB, and empyema are significant risk factors for treatment delay in patients with pleural tuberculosis.
Answers are grounded in this paper and cite their sources.
May warrant closer monitoring to mitigate delays in pleural TB; hypothesis-generating for interventional trials.
BACKGROUND: Current strategies for the prevention, diagnosis and treatment of pleural TB have been inadequate, several challenges and issues related with pleural TB have been reported. AIM: To summarize the main features of pleural tuberculosis (TB) and determine the risk factors in treatment delay. DESIGN: Retrospective analysis of hospital records. METHODS: Consecutive confirmed TB patients with pleural effusion were enrolled in the study. Demographic and epidemiological data were collected from electronic medical records. Treatment delay duration was stratified into two categories: <30 days and ≥30 days. Multivariate logistic regression analysis was used to evaluate risk factors for the delay. RESULTS: From July 2011 to September 2015, a total of 723 patients were enrolled, 72.1% of patients had pulmonary TB, 8.9% had empyema, 8.9% were multidrug-resistant TB (MDR-TB). Multivariate analysis revealed that MDR-TB (odds ratios (OR) = 2.485, 95% confidence interval (CI) 1.347, 4.587), pulmonary TB (OR = 1.452, 95% CI 1.010, 2.087) and empyema (OR = 4.355, 95% CI 2.185, 8.680) were significant risk factors for treatment delay, while fever (OR= 0.519, 95% CI 0.362, 0.744) as well as pleural protein (≥45 g/l) (OR=0.470, 95% CI 0.332, 0.667) were the protective factors. CONCLUSION: MDR-TB, pulmonary TB and empyema were significant risk factors for treatment delay, while fever and high pleural protein were protective factors. Tuberculous empyema remains a major problem in China, adequate awareness should be created for the management.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2018) conducted an observational in Pleural tuberculosis (n=723). MDR-TB, pulmonary TB, and empyema was evaluated on Treatment delay ≥30 days (OR 2.485, 95% CI 1.347-4.587). MDR-TB, pulmonary TB, and empyema were significant risk factors for treatment delay ≥30 days in patients with pleural tuberculosis.
Synapse has enriched 10 related papers. Consider them for comparative context: